<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00950599</url>
  </required_header>
  <id_info>
    <org_study_id>CV181-008</org_study_id>
    <nct_id>NCT00950599</nct_id>
  </id_info>
  <brief_title>Study of Multiple Doses of Saxagliptin (BMS-477118)</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Trial to Evaluate the Safety and Efficacy of BMS-477118 as Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the positive efficacy trend among doses of saxagliptin (BMS-477118) in subjects
      with Type 2 diabetes mellitus by assessing the change from baseline in HbA1c following 12
      weeks of double-blind treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">May 2004</completion_date>
  <primary_completion_date type="Actual">May 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of Test for Positive Efficacy Trend in Change From Baseline in Hemoglobin A1c (A1C) at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Positive efficacy trend among doses of saxagliptin by assessing the adjusted mean change from baseline in A1C in the 0-40 mg cohort. The unit of measurement for A1C is percent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in A1C at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in A1C achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in A1C at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in A1C achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Serum Glucose (FSG) at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in FSG achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FSG at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in FSG achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fructosamine at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in fructosamine achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fructosamine at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in fructosamine achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in fasting insulin achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in insulin achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in C-peptide at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in C-peptide achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in C-peptide at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in C-peptide achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postprandial Glucose 0-60 Minute Area Under the Curve (AUC) at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose 0-60 minute AUC response to a liquid meal tolerance test (MTT) achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts. Area Under the Curve (AUC) here is defined as the area under the plot of the serum concentration of glucose against time after ingesting the meal for the first 60 minutes after the subject drinks the liquid meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postprandial Glucose 0-60 Minute AUC at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postprandial Insulin 0-60 Minute AUC at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postprandial Insulin 0-60 Minute AUC at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postprandial C-peptide 0-60 Minute AUC at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postprandial C-peptide 0-60 Minute AUC at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (postprandial) C-peptide 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 15-minute Postprandial Glucose at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial Glucose at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial glucose 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 60-minute Postprandial Glucose at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 15-minute Postprandial Glucose at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial Glucose at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial glucose 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 60-minute Postprandial Glucose at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 15-minute Postprandial Insulin at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial insulin 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial Insulin at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 60-minute Postprandial Insulin at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 15-minute Postprandial Insulin at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial Insulin at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 60-minute Postprandial Insulin at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 15-minute Postprandial C-peptide at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial C-peptide at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 60-minute Postprandial C-peptide at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 15-minute Postprandial C-peptide at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial C-peptide at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 60-minute Postprandial C-peptide at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 15-minute Postprandial Glucose Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial Glucose Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 60-minute Postprandial Glucose Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 15-minute Postprandial Glucose Excursion at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial Glucose Excursion at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 60-minute Postprandial Glucose Excursion at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 15-minute Postprandial Insulin Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial Insulin Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 60-minute Postprandial Insulin Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 15-minute Postprandial Insulin Excursion at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial Insulin Excursion at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 60-minute Postprandial Insulin Excursion at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 15-minute Postprandial C-peptide Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial C-peptide Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 60-minute Postprandial C-peptide Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 15-minute Postprandial C-peptide Excursion at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial C-peptide Excursion at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 60-minute Postprandial C-peptide Excursion at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial Glucagon at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) glucagon 30 minutes after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial Glucagon at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) glucagon 30 minutes after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial Free Fatty Acids (FFA) at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) FFA 30 minutes after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial FFA at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) FFA 30 minutes after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial Glucagon Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) glucagon excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial Glucagon Excursion at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) glucagon excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial FFA Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) FFA excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Postprandial FFA Excursion at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Adjusted mean change from baseline in postprandial (after mealtime) FFA excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 15-minute Insulinogenic Index at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Mean change from baseline in 15-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 15-minute Insulinogenic Index at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Mean change from baseline in 15-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Insulinogenic Index at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts.</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Mean change from baseline in 30-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 30-minute Insulinogenic Index at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Mean change from baseline in 30-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Matsuda Index at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Mean change from baseline in Matsuda index achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts. The Matsuda index is a scale designed to give numbers between 0 and 12, with a linear relationship to other indices of insulin sensitivity. The higher the number, the better the insulin sensitivity (improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Matsuda Index at Week 12 in the 0-40 mg Cohort</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Mean change from baseline in Matsuda index achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort. The Matsuda index is a scale designed to give numbers between 0 and 12, with a linear relationship to other indices of insulin sensitivity. The higher the number, the better the insulin sensitivity (improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in A1C at 2 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 14</time_frame>
    <description>Mean change from baseline in A1C achieved at each dose of saxagliptin during the Follow-Up period at Week 14 in the 0-40 mg cohort and at Week 8 in the 0 &amp; 100 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in A1C at 4 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 10, Week 16</time_frame>
    <description>Mean change from baseline in A1C achieved at each dose of saxagliptin during the Follow-Up period at Week 16 in the 0-40 mg cohort and at Week 10 in the 0 &amp; 100 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FSG at 2 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 8, Week 14</time_frame>
    <description>Mean change from baseline in FSG achieved at each dose of saxagliptin during Follow-Up period at Week 14 in the 0-40 mg cohort and at Week 8 in the 0 &amp; 100 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FSG at 4 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 10, Week 16</time_frame>
    <description>Mean change from baseline in FSG achieved at each dose of saxagliptin during the follow-up period at Week 16 in the 0-40 mg cohort and at Week 10 in the 0 &amp; 100 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fructosamine at 2 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 8, Week 14</time_frame>
    <description>Mean change from baseline in fructosamine achieved at each dose of saxagliptin during the Follow-up period at Week 14 in the 0-40 mg cohort and at Week 8 in the 0 &amp; 100 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fructosamine at 4 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 &amp; 100 mg Cohorts</measure>
    <time_frame>Baseline, Week 10, Week 16</time_frame>
    <description>Mean change from baseline in fructosamine achieved at each dose of saxagliptin during the Follow-up period at Week 16 in the 0-40 mg cohort and at Week 10 in the 0 &amp; 100 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in A1C at Week 6 by Baseline A1C Category in the 0 &amp; 100 Cohort</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in A1C achieved at each dose of saxagliptin at Week 6 in subjects with baseline A1C &lt;7%, ≥7% to &lt;8%, ≥8% to &lt;9%, and ≥9% in the 0 &amp; 100 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FSG at Week 6 in Subjects by Baseline FSG Category in the 0 &amp; 100 mg Cohort.</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in FSG achieved at each dose of saxagliptin at Week 6 in subjects with baseline FSG &lt;140 mg/dL, ≥140 mg/dL to &lt;180 mg/dL, and ≥ 180 mg/dL in the 0 &amp; 100 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 60 Minute Postprandial Glucose at Week 6 by Baseline Category in the 0 &amp; 100 mg Cohort</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in 60-minute postprandial glucose achieved at each dose of saxagliptin at Week 6 in subjects with baseline 60-minute postprandial glucose &lt;140 mg/dL, ≥140 to &lt;200 mg/dL, and ≥200 mg/dL in the 0 &amp; 100 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving A1C &lt; 7% at Week 6 in the 0 &amp; 100 mg Cohort</measure>
    <time_frame>Week 6</time_frame>
    <description>Percentage of participants achieving A1C &lt; 7%, the American Diabetic Association's defined goal for glycemia, at each dose of saxagliptin at Week 6 in the 0 &amp; 100 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 60-minute Postprandial FFA Excursion at Week 6 in the 0 &amp; 100 mg Cohort</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial FFA excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0 &amp; 100 mg cohort. (Note: this analysis was not performed.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 60-minute Postprandial Glucagon Excursion at Week 6 in the 0 &amp; 100 mg Cohort</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Adjusted mean change from baseline in postprandial glucagon excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0 &amp; 100 mg cohort. (Note: this analysis was not performed.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuations During the Double-Blind Phase Due to Lack of Glycemic Control</measure>
    <time_frame>Week 4, Week 6</time_frame>
    <description>Number of participants discontinuing from the double-blind phase due to lack of glycemic control at Week 4 and Week 6. (Note: this analysis was not performed.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Double-Blind Treatment Period in the 0-40 mg Cohort</measure>
    <time_frame>up to Week 12 for AEs; up to 30 days post-double-blind period but prior to follow-up period if any for SAEs and up to 30 days post-double-blind period for Discontinuations</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Double-Blind Treatment Period in the 0 &amp; 100 mg Cohort</measure>
    <time_frame>up to Week 6 for AEs; up to 30 days post-double-blind period but prior to follow-up period if any for SAEs and up to 30 days post-double-blind period for Discontinuations</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Follow-up Period in the 0-40 mg Cohort</measure>
    <time_frame>From Week 12 to Week 16 for AEs; up to 30 days post follow-up in both cohorts for SAEs and Discontinuations</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Follow-up Period in the 0 &amp; 100 mg Cohort</measure>
    <time_frame>From Week 6 to Week 10 for AEs; up to 30 days post follow-up in both cohorts for SAEs and Discontinuations</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">423</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Saxagliptin (2.5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin (5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin (10 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin (20 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin (40 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin (100 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Tablets, Oral, 2.5 mg, once daily, 12 weeks</description>
    <arm_group_label>Saxagliptin (2.5 mg)</arm_group_label>
    <other_name>BMS-477118</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Tablets, Oral, 5 mg, once daily, 12 weeks</description>
    <arm_group_label>Saxagliptin (5 mg)</arm_group_label>
    <other_name>BMS-477118</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Tablets, Oral, 10 mg, once daily, 12 weeks</description>
    <arm_group_label>Saxagliptin (10 mg)</arm_group_label>
    <other_name>BMS-477118</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Tablets, Oral, 20 mg, once daily, 12 weeks</description>
    <arm_group_label>Saxagliptin (20 mg)</arm_group_label>
    <other_name>BMS-477118</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Tablets, Oral, 40 mg, once daily, 12 weeks</description>
    <arm_group_label>Saxagliptin (40 mg)</arm_group_label>
    <other_name>BMS-477118</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Tablets, Oral, 100 mg, once daily, 6 weeks</description>
    <arm_group_label>Saxagliptin (100 mg)</arm_group_label>
    <other_name>BMS-477118</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, Oral, 0 mg, once daily, 6 and 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes who are drug-naive

          -  Screening HbA1c ≥ 6.8% and ≤ 9.7%

          -  Screening fasting or random C-peptide &gt; 0.5 ng/mL

          -  &lt; 35 years old must be negative for anti-GAD antibodies

          -  Body Mass Index &lt; 35 kg/m2

        Exclusion Criteria:

          -  Symptoms of poorly controlled diabetes

          -  History of diabetic ketoacidosis, hyperosmolar nonketotic coma, or insulin therapy
             within one year of screening

          -  Receipt of oral antihyperglycemic medications for more than six months in total since
             diagnosis

          -  Significant cardiovascular history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <reference>
    <citation>Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008 May;10(5):376-86. doi: 10.1111/j.1463-1326.2008.00876.x. Epub 2008 Mar 18.</citation>
    <PMID>18355324</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2009</study_first_submitted>
  <study_first_submitted_qc>July 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2009</study_first_posted>
  <results_first_submitted>August 28, 2009</results_first_submitted>
  <results_first_submitted_qc>February 4, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2010</results_first_posted>
  <last_update_submitted>March 16, 2015</last_update_submitted>
  <last_update_submitted_qc>March 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          <description>The Saxagliptin 2.5 mg group includes data from subjects randomized to receive blinded Saxagliptin 2.5 mg for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          <description>The Saxagliptin 5 mg group includes data from subjects randomized to receive blinded Saxagliptin 5 mg for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          <description>The Saxagliptin 10 mg group includes data from subjects randomized to receive blinded Saxagliptin 10 mg for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          <description>The Saxagliptin 20 mg group includes data from subjects randomized to receive blinded Saxagliptin 20 mg for 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          <description>The Saxagliptin 40 mg group includes data from subjects randomized to receive blinded Saxagliptin 40 mg for 12 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Placebo (0-40 mg Cohort)</title>
          <description>The placebo group includes data from subjects randomized to receive blinded placebo for 12 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          <description>The Saxagliptin 100 mg group includes data from subjects randomized to receive blinded Saxagliptin 100 mg for 6 weeks.</description>
        </group>
        <group group_id="P8">
          <title>Placebo (0 &amp; 100 mg Cohort)</title>
          <description>The placebo group includes data from subjects randomized to receive blinded placebo for 6 weeks.</description>
        </group>
        <group group_id="P9">
          <title>Saxa 0-40 mg Cohort (Follow-up Period)</title>
          <description>The follow-up period is 4 weeks and includes: subjects completing 12 weeks of double-blind dosing (received single blind placebo); subjects who met the hyperglycemic rescue criteria (received open-label metformin in addition to placebo); subjects meeting hyperglycemic discontinuation criteria (received open-label metformin); and subjects who discontinued the double-blind period for reasons other than hyperglycemia (received metformin only if clinically indicated). Open-label metformin was (initiated at 500 mg per day and titrated in 500 mg increments after 2 weeks or as clinically indicated). Additional or alternative antihyperglycemic agents were permitted during the follow-up period as clinically indicated.</description>
        </group>
        <group group_id="P10">
          <title>Saxa 0 &amp; 100 mg Cohort (Follow-up Period)</title>
          <description>The follow-up period is 4 weeks and includes: subjects completing 6 weeks of double-blind dosing (received single blind placebo); subjects who met the hyperglycemic rescue criteria (received open-label metformin in addition to placebo); subjects meeting hyperglycemic discontinuation criteria (received open-label metformin); and subjects who discontinued the double-blind period for reasons other than hyperglycemia (received metformin only if clinically indicated). Open-label metformin was (initiated at 500 mg per day and titrated in 500 mg increments after 2 weeks or as clinically indicated). Additional or alternative antihyperglycemic agents were permitted during the follow-up period as clinically indicated.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="54"/>
                <participants group_id="P5" count="52"/>
                <participants group_id="P6" count="67"/>
                <participants group_id="P7" count="44"/>
                <participants group_id="P8" count="41"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48">Completed 12 weeks of treatment</participants>
                <participants group_id="P2" count="37">Completed 12 weeks of treatment</participants>
                <participants group_id="P3" count="54">Completed 12 weeks of treatment</participants>
                <participants group_id="P4" count="43">Completed 12 weeks of treatment</participants>
                <participants group_id="P5" count="45">Completed 12 weeks of treatment</participants>
                <participants group_id="P6" count="55">Completed 12 weeks of treatment</participants>
                <participants group_id="P7" count="44">Completed 12 weeks of treatment</participants>
                <participants group_id="P8" count="35">Completed 12 weeks of treatment</participants>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative reason by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor/Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject no longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-Up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="309">those completing double blind period (DB) + those rescued/discontinued from DB due to hyperglycemia</participants>
                <participants group_id="P10" count="80">those completing double blind period (DB) + those rescued/discontinued from DB due to hyperglycemia</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="296"/>
                <participants group_id="P10" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="13"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor/Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
        </group>
        <group group_id="B2">
          <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
        </group>
        <group group_id="B3">
          <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
        </group>
        <group group_id="B4">
          <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
        </group>
        <group group_id="B5">
          <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
        </group>
        <group group_id="B6">
          <title>Placebo (0-40 mg Cohort)</title>
        </group>
        <group group_id="B7">
          <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
        </group>
        <group group_id="B8">
          <title>Placebo (0 &amp; 100 mg Cohort)</title>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="63"/>
            <count group_id="B4" value="54"/>
            <count group_id="B5" value="52"/>
            <count group_id="B6" value="67"/>
            <count group_id="B7" value="44"/>
            <count group_id="B8" value="41"/>
            <count group_id="B9" value="423"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="55"/>
                    <measurement group_id="B7" value="38"/>
                    <measurement group_id="B8" value="35"/>
                    <measurement group_id="B9" value="362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="17"/>
                    <measurement group_id="B8" value="18"/>
                    <measurement group_id="B9" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="42"/>
                    <measurement group_id="B7" value="27"/>
                    <measurement group_id="B8" value="23"/>
                    <measurement group_id="B9" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Analysis of Test for Positive Efficacy Trend in Change From Baseline in Hemoglobin A1c (A1C) at Week 12 in the 0-40 mg Cohort</title>
        <description>Positive efficacy trend among doses of saxagliptin by assessing the adjusted mean change from baseline in A1C in the 0-40 mg cohort. The unit of measurement for A1C is percent.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of positive efficacy trend in change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Test for Positive Efficacy Trend in Change From Baseline in Hemoglobin A1c (A1C) at Week 12 in the 0-40 mg Cohort</title>
          <description>Positive efficacy trend among doses of saxagliptin by assessing the adjusted mean change from baseline in A1C in the 0-40 mg cohort. The unit of measurement for A1C is percent.</description>
          <population>Randomized participants. To be included in analysis of positive efficacy trend in change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>percentage of glycosylated hemoglobins</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="0.80"/>
                    <measurement group_id="O2" value="-0.95" spread="0.97"/>
                    <measurement group_id="O3" value="-0.81" spread="0.91"/>
                    <measurement group_id="O4" value="-0.74" spread="0.93"/>
                    <measurement group_id="O5" value="-0.78" spread="1.04"/>
                    <measurement group_id="O6" value="-0.29" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A test for log-linear trend across saxagliptin doses was performed using a linear contrast among the saxagliptin doses from an analysis of covariance (ANCOVA) model. The ANCOVA model was the same model used for the first secondary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9888</p_value>
            <p_value_desc>A significance level of alpha = 0.05 was used for the trend test.</p_value_desc>
            <method>Kruskal-Wallis</method>
            <method_desc>ANCOVA Model: post-pre=pre treatment.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in A1C at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in A1C achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in A1C achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>percentage of glycosylated hemoglobins</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.12"/>
                    <measurement group_id="O2" value="-0.90" spread="0.14"/>
                    <measurement group_id="O3" value="-0.81" spread="0.11"/>
                    <measurement group_id="O4" value="-0.74" spread="0.12"/>
                    <measurement group_id="O5" value="-0.80" spread="0.12"/>
                    <measurement group_id="O6" value="-0.27" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9888</p_value>
            <p_value_desc>Positive efficacy trend among doses of saxagliptin by assessing the adjusted mean change from baseline in A1C in the 0-40 mg cohort.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA Model: post-pre=pretreatment. Contrast Coefficients: -2, -1, 0, 1 2.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in A1C at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in A1C achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in A1C achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>percentage of glycosylated hemoglobins</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="57"/>
                <count group_id="O7" value="43"/>
                <count group_id="O8" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="0.09"/>
                    <measurement group_id="O2" value="-0.72" spread="0.10"/>
                    <measurement group_id="O3" value="-0.67" spread="0.09"/>
                    <measurement group_id="O4" value="-0.68" spread="0.09"/>
                    <measurement group_id="O5" value="-0.82" spread="0.09"/>
                    <measurement group_id="O6" value="-0.33" spread="0.08"/>
                    <measurement group_id="O7" value="-1.09" spread="0.09"/>
                    <measurement group_id="O8" value="-0.36" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Serum Glucose (FSG) at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in FSG achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Serum Glucose (FSG) at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in FSG achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="63"/>
                <count group_id="O7" value="43"/>
                <count group_id="O8" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.71" spread="3.68"/>
                    <measurement group_id="O2" value="-18.63" spread="3.82"/>
                    <measurement group_id="O3" value="-16.10" spread="3.32"/>
                    <measurement group_id="O4" value="-14.66" spread="3.57"/>
                    <measurement group_id="O5" value="-18.34" spread="3.67"/>
                    <measurement group_id="O6" value="-6.20" spread="3.26"/>
                    <measurement group_id="O7" value="-26.33" spread="3.53"/>
                    <measurement group_id="O8" value="-3.29" spread="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FSG at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in FSG achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FSG at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in FSG achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.85" spread="4.61"/>
                    <measurement group_id="O2" value="-21.68" spread="4.80"/>
                    <measurement group_id="O3" value="-15.91" spread="4.16"/>
                    <measurement group_id="O4" value="-13.61" spread="4.48"/>
                    <measurement group_id="O5" value="-16.36" spread="4.60"/>
                    <measurement group_id="O6" value="2.81" spread="4.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fructosamine at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in fructosamine achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fructosamine at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in fructosamine achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="62"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.02" spread="3.91"/>
                    <measurement group_id="O2" value="-21.87" spread="4.29"/>
                    <measurement group_id="O3" value="-24.72" spread="3.65"/>
                    <measurement group_id="O4" value="-23.96" spread="3.88"/>
                    <measurement group_id="O5" value="-26.03" spread="4.07"/>
                    <measurement group_id="O6" value="-9.26" spread="3.62"/>
                    <measurement group_id="O7" value="-28.03" spread="3.74"/>
                    <measurement group_id="O8" value="-0.16" spread="4.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fructosamine at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in fructosamine achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fructosamine at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in fructosamine achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.89" spread="4.64"/>
                    <measurement group_id="O2" value="-25.23" spread="5.14"/>
                    <measurement group_id="O3" value="-21.31" spread="4.36"/>
                    <measurement group_id="O4" value="-22.30" spread="4.64"/>
                    <measurement group_id="O5" value="-26.30" spread="4.82"/>
                    <measurement group_id="O6" value="-8.57" spread="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Insulin at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in fasting insulin achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0, 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0, 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in fasting insulin achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="39"/>
                <count group_id="O8" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="1.22"/>
                    <measurement group_id="O2" value="1.05" spread="1.26"/>
                    <measurement group_id="O3" value="-0.99" spread="1.11"/>
                    <measurement group_id="O4" value="-0.17" spread="1.18"/>
                    <measurement group_id="O5" value="0.38" spread="1.23"/>
                    <measurement group_id="O6" value="0.08" spread="1.11"/>
                    <measurement group_id="O7" value="-2.03" spread="1.09"/>
                    <measurement group_id="O8" value="-0.61" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Insulin at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in insulin achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in insulin achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="1.63"/>
                    <measurement group_id="O2" value="1.02" spread="1.93"/>
                    <measurement group_id="O3" value="1.41" spread="1.54"/>
                    <measurement group_id="O4" value="0.76" spread="1.74"/>
                    <measurement group_id="O5" value="2.29" spread="1.65"/>
                    <measurement group_id="O6" value="1.29" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in C-peptide at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in C-peptide achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-peptide at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in C-peptide achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="39"/>
                <count group_id="O8" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.12"/>
                    <measurement group_id="O2" value="-0.19" spread="0.13"/>
                    <measurement group_id="O3" value="-0.06" spread="0.11"/>
                    <measurement group_id="O4" value="-0.02" spread="0.12"/>
                    <measurement group_id="O5" value="-0.03" spread="0.13"/>
                    <measurement group_id="O6" value="-0.08" spread="0.11"/>
                    <measurement group_id="O7" value="-0.52" spread="0.12"/>
                    <measurement group_id="O8" value="-0.13" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in C-peptide at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in C-peptide achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-peptide at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in C-peptide achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.14"/>
                    <measurement group_id="O2" value="-0.13" spread="0.16"/>
                    <measurement group_id="O3" value="-0.09" spread="0.13"/>
                    <measurement group_id="O4" value="0.01" spread="0.14"/>
                    <measurement group_id="O5" value="-0.02" spread="0.14"/>
                    <measurement group_id="O6" value="0.02" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postprandial Glucose 0-60 Minute Area Under the Curve (AUC) at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose 0-60 minute AUC response to a liquid meal tolerance test (MTT) achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts. Area Under the Curve (AUC) here is defined as the area under the plot of the serum concentration of glucose against time after ingesting the meal for the first 60 minutes after the subject drinks the liquid meal.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postprandial Glucose 0-60 Minute Area Under the Curve (AUC) at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose 0-60 minute AUC response to a liquid meal tolerance test (MTT) achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts. Area Under the Curve (AUC) here is defined as the area under the plot of the serum concentration of glucose against time after ingesting the meal for the first 60 minutes after the subject drinks the liquid meal.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mg*min/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="59"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1226" spread="318"/>
                    <measurement group_id="O2" value="-1503" spread="353"/>
                    <measurement group_id="O3" value="-1312" spread="290"/>
                    <measurement group_id="O4" value="-1246" spread="320"/>
                    <measurement group_id="O5" value="-1626" spread="324"/>
                    <measurement group_id="O6" value="-461" spread="280"/>
                    <measurement group_id="O7" value="-2035" spread="263"/>
                    <measurement group_id="O8" value="-664" spread="283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postprandial Glucose 0-60 Minute AUC at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postprandial Glucose 0-60 Minute AUC at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mg*min/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1121" spread="320"/>
                    <measurement group_id="O2" value="-1505" spread="369"/>
                    <measurement group_id="O3" value="-1730" spread="289"/>
                    <measurement group_id="O4" value="-1377" spread="322"/>
                    <measurement group_id="O5" value="-1520" spread="314"/>
                    <measurement group_id="O6" value="174" spread="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postprandial Insulin 0-60 Minute AUC at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postprandial Insulin 0-60 Minute AUC at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>uU*min/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="57"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234.2" spread="149.5"/>
                    <measurement group_id="O2" value="293.2" spread="162.3"/>
                    <measurement group_id="O3" value="120.0" spread="136.6"/>
                    <measurement group_id="O4" value="165.4" spread="145.3"/>
                    <measurement group_id="O5" value="28.8" spread="152.4"/>
                    <measurement group_id="O6" value="164.6" spread="130.5"/>
                    <measurement group_id="O7" value="-296.0" spread="160.4"/>
                    <measurement group_id="O8" value="261.9" spread="167.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postprandial Insulin 0-60 Minute AUC at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postprandial Insulin 0-60 Minute AUC at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>uU*min/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2" spread="179.9"/>
                    <measurement group_id="O2" value="283.4" spread="218.0"/>
                    <measurement group_id="O3" value="114.2" spread="163.6"/>
                    <measurement group_id="O4" value="336.8" spread="177.7"/>
                    <measurement group_id="O5" value="195.6" spread="180.7"/>
                    <measurement group_id="O6" value="30.3" spread="155.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postprandial C-peptide 0-60 Minute AUC at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postprandial C-peptide 0-60 Minute AUC at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>ng*min/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="57"/>
                <count group_id="O7" value="34"/>
                <count group_id="O8" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="9.4"/>
                    <measurement group_id="O2" value="7.6" spread="10.3"/>
                    <measurement group_id="O3" value="-5.5" spread="8.7"/>
                    <measurement group_id="O4" value="5.4" spread="9.2"/>
                    <measurement group_id="O5" value="0.2" spread="9.5"/>
                    <measurement group_id="O6" value="-0.8" spread="8.3"/>
                    <measurement group_id="O7" value="-19.7" spread="9.8"/>
                    <measurement group_id="O8" value="0.8" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postprandial C-peptide 0-60 Minute AUC at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (postprandial) C-peptide 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postprandial C-peptide 0-60 Minute AUC at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (postprandial) C-peptide 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>ng*min/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="11.5"/>
                    <measurement group_id="O2" value="4.8" spread="14.0"/>
                    <measurement group_id="O3" value="-1.6" spread="10.5"/>
                    <measurement group_id="O4" value="7.1" spread="11.4"/>
                    <measurement group_id="O5" value="-3.4" spread="11.6"/>
                    <measurement group_id="O6" value="-4.0" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 15-minute Postprandial Glucose at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 15-minute Postprandial Glucose at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="39"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.24" spread="5.22"/>
                    <measurement group_id="O2" value="-16.53" spread="5.75"/>
                    <measurement group_id="O3" value="-16.78" spread="4.72"/>
                    <measurement group_id="O4" value="-14.35" spread="4.92"/>
                    <measurement group_id="O5" value="-26.03" spread="5.38"/>
                    <measurement group_id="O6" value="-9.30" spread="4.76"/>
                    <measurement group_id="O7" value="-25.99" spread="4.30"/>
                    <measurement group_id="O8" value="-6.80" spread="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial Glucose at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial glucose 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial Glucose at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial glucose 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="39"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.45" spread="6.09"/>
                    <measurement group_id="O2" value="-29.31" spread="6.80"/>
                    <measurement group_id="O3" value="-25.32" spread="5.52"/>
                    <measurement group_id="O4" value="-23.93" spread="5.74"/>
                    <measurement group_id="O5" value="-30.60" spread="6.12"/>
                    <measurement group_id="O6" value="-7.81" spread="5.57"/>
                    <measurement group_id="O7" value="-36.33" spread="4.99"/>
                    <measurement group_id="O8" value="-10.94" spread="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 60-minute Postprandial Glucose at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 60-minute Postprandial Glucose at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.45" spread="6.85"/>
                    <measurement group_id="O2" value="-39.99" spread="7.80"/>
                    <measurement group_id="O3" value="-27.51" spread="6.21"/>
                    <measurement group_id="O4" value="-24.32" spread="6.48"/>
                    <measurement group_id="O5" value="-34.44" spread="6.90"/>
                    <measurement group_id="O6" value="-4.96" spread="6.29"/>
                    <measurement group_id="O7" value="-44.58" spread="5.65"/>
                    <measurement group_id="O8" value="-17.22" spread="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 15-minute Postprandial Glucose at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 15-minute Postprandial Glucose at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.89" spread="4.78"/>
                    <measurement group_id="O2" value="-16.45" spread="5.58"/>
                    <measurement group_id="O3" value="-19.57" spread="4.35"/>
                    <measurement group_id="O4" value="-18.70" spread="4.94"/>
                    <measurement group_id="O5" value="-20.75" spread="4.77"/>
                    <measurement group_id="O6" value="0.77" spread="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial Glucose at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial glucose 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial Glucose at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial glucose 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.79" spread="5.35"/>
                    <measurement group_id="O2" value="-24.04" spread="6.21"/>
                    <measurement group_id="O3" value="-28.59" spread="4.92"/>
                    <measurement group_id="O4" value="-23.56" spread="5.52"/>
                    <measurement group_id="O5" value="-20.42" spread="5.25"/>
                    <measurement group_id="O6" value="-2.08" spread="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 60-minute Postprandial Glucose at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 60-minute Postprandial Glucose at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.42" spread="6.73"/>
                    <measurement group_id="O2" value="-35.30" spread="7.84"/>
                    <measurement group_id="O3" value="-41.04" spread="6.14"/>
                    <measurement group_id="O4" value="-27.54" spread="6.97"/>
                    <measurement group_id="O5" value="-33.98" spread="6.71"/>
                    <measurement group_id="O6" value="-1.41" spread="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 15-minute Postprandial Insulin at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial insulin 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 15-minute Postprandial Insulin at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial insulin 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="58"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.36" spread="2.74"/>
                    <measurement group_id="O2" value="2.22" spread="3.02"/>
                    <measurement group_id="O3" value="2.47" spread="2.53"/>
                    <measurement group_id="O4" value="3.11" spread="2.66"/>
                    <measurement group_id="O5" value="-0.60" spread="2.77"/>
                    <measurement group_id="O6" value="0.60" spread="2.44"/>
                    <measurement group_id="O7" value="-1.72" spread="3.07"/>
                    <measurement group_id="O8" value="1.63" spread="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial Insulin at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial Insulin at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="58"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.20" spread="3.39"/>
                    <measurement group_id="O2" value="8.51" spread="3.81"/>
                    <measurement group_id="O3" value="2.04" spread="3.18"/>
                    <measurement group_id="O4" value="1.10" spread="3.35"/>
                    <measurement group_id="O5" value="-0.33" spread="3.40"/>
                    <measurement group_id="O6" value="4.82" spread="3.04"/>
                    <measurement group_id="O7" value="-4.44" spread="3.30"/>
                    <measurement group_id="O8" value="7.69" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 60-minute Postprandial Insulin at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 60-minute Postprandial Insulin at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="58"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="4.06"/>
                    <measurement group_id="O2" value="4.45" spread="4.49"/>
                    <measurement group_id="O3" value="0.25" spread="3.73"/>
                    <measurement group_id="O4" value="4.75" spread="3.93"/>
                    <measurement group_id="O5" value="-0.13" spread="4.11"/>
                    <measurement group_id="O6" value="3.33" spread="3.59"/>
                    <measurement group_id="O7" value="-8.17" spread="4.37"/>
                    <measurement group_id="O8" value="1.83" spread="4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 15-minute Postprandial Insulin at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 15-minute Postprandial Insulin at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" spread="3.67"/>
                    <measurement group_id="O2" value="5.79" spread="4.49"/>
                    <measurement group_id="O3" value="2.87" spread="3.37"/>
                    <measurement group_id="O4" value="6.81" spread="3.74"/>
                    <measurement group_id="O5" value="-1.48" spread="3.65"/>
                    <measurement group_id="O6" value="4.70" spread="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial Insulin at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial Insulin at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="4.09"/>
                    <measurement group_id="O2" value="10.71" spread="5.01"/>
                    <measurement group_id="O3" value="2.48" spread="3.79"/>
                    <measurement group_id="O4" value="5.90" spread="4.16"/>
                    <measurement group_id="O5" value="6.14" spread="4.04"/>
                    <measurement group_id="O6" value="1.19" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 60-minute Postprandial Insulin at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 60-minute Postprandial Insulin at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" spread="4.36"/>
                    <measurement group_id="O2" value="4.61" spread="5.31"/>
                    <measurement group_id="O3" value="0.38" spread="3.95"/>
                    <measurement group_id="O4" value="4.99" spread="4.39"/>
                    <measurement group_id="O5" value="2.42" spread="4.40"/>
                    <measurement group_id="O6" value="-2.22" spread="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 15-minute Postprandial C-peptide at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 15-minute Postprandial C-peptide at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="58"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.17"/>
                    <measurement group_id="O2" value="-0.09" spread="0.19"/>
                    <measurement group_id="O3" value="-0.12" spread="0.16"/>
                    <measurement group_id="O4" value="0.17" spread="0.17"/>
                    <measurement group_id="O5" value="-0.14" spread="0.17"/>
                    <measurement group_id="O6" value="-0.13" spread="0.15"/>
                    <measurement group_id="O7" value="-0.27" spread="0.17"/>
                    <measurement group_id="O8" value="0.01" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial C-peptide at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial C-peptide at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="58"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.20"/>
                    <measurement group_id="O2" value="0.16" spread="0.23"/>
                    <measurement group_id="O3" value="-0.01" spread="0.19"/>
                    <measurement group_id="O4" value="-0.06" spread="0.20"/>
                    <measurement group_id="O5" value="-0.02" spread="0.21"/>
                    <measurement group_id="O6" value="0.03" spread="0.18"/>
                    <measurement group_id="O7" value="-0.35" spread="0.21"/>
                    <measurement group_id="O8" value="0.05" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 60-minute Postprandial C-peptide at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 60-minute Postprandial C-peptide at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="58"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.22"/>
                    <measurement group_id="O2" value="0.36" spread="0.25"/>
                    <measurement group_id="O3" value="-0.16" spread="0.21"/>
                    <measurement group_id="O4" value="0.20" spread="0.22"/>
                    <measurement group_id="O5" value="0.19" spread="0.22"/>
                    <measurement group_id="O6" value="0.24" spread="0.20"/>
                    <measurement group_id="O7" value="-0.33" spread="0.25"/>
                    <measurement group_id="O8" value="-0.10" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 15-minute Postprandial C-peptide at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 15-minute Postprandial C-peptide at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.23"/>
                    <measurement group_id="O2" value="0.11" spread="0.28"/>
                    <measurement group_id="O3" value="-0.12" spread="0.21"/>
                    <measurement group_id="O4" value="-0.02" spread="0.23"/>
                    <measurement group_id="O5" value="-0.27" spread="0.23"/>
                    <measurement group_id="O6" value="0.07" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial C-peptide at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial C-peptide at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.23"/>
                    <measurement group_id="O2" value="0.27" spread="0.29"/>
                    <measurement group_id="O3" value="0.05" spread="0.22"/>
                    <measurement group_id="O4" value="0.19" spread="0.24"/>
                    <measurement group_id="O5" value="0.12" spread="0.23"/>
                    <measurement group_id="O6" value="-0.14" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 60-minute Postprandial C-peptide at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 60-minute Postprandial C-peptide at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.26"/>
                    <measurement group_id="O2" value="0.18" spread="0.31"/>
                    <measurement group_id="O3" value="-0.02" spread="0.23"/>
                    <measurement group_id="O4" value="0.22" spread="0.26"/>
                    <measurement group_id="O5" value="0.01" spread="0.26"/>
                    <measurement group_id="O6" value="0.22" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 15-minute Postprandial Glucose Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 15-minute Postprandial Glucose Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="59"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="2.54"/>
                    <measurement group_id="O2" value="-5.23" spread="2.82"/>
                    <measurement group_id="O3" value="-1.15" spread="2.36"/>
                    <measurement group_id="O4" value="3.48" spread="2.64"/>
                    <measurement group_id="O5" value="-0.95" spread="2.65"/>
                    <measurement group_id="O6" value="-2.37" spread="2.30"/>
                    <measurement group_id="O7" value="-1.12" spread="2.35"/>
                    <measurement group_id="O8" value="1.02" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial Glucose Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial Glucose Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="59"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.39" spread="3.24"/>
                    <measurement group_id="O2" value="-15.91" spread="3.64"/>
                    <measurement group_id="O3" value="-6.92" spread="3.05"/>
                    <measurement group_id="O4" value="-5.68" spread="3.34"/>
                    <measurement group_id="O5" value="-6.89" spread="3.30"/>
                    <measurement group_id="O6" value="-2.40" spread="2.92"/>
                    <measurement group_id="O7" value="-12.76" spread="3.87"/>
                    <measurement group_id="O8" value="-0.79" spread="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 60-minute Postprandial Glucose Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 60-minute Postprandial Glucose Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="59"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.08" spread="4.01"/>
                    <measurement group_id="O2" value="-23.94" spread="4.57"/>
                    <measurement group_id="O3" value="-12.94" spread="3.75"/>
                    <measurement group_id="O4" value="-6.10" spread="4.14"/>
                    <measurement group_id="O5" value="-11.88" spread="4.09"/>
                    <measurement group_id="O6" value="-1.31" spread="3.63"/>
                    <measurement group_id="O7" value="-20.69" spread="4.09"/>
                    <measurement group_id="O8" value="-8.59" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 15-minute Postprandial Glucose Excursion at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 15-minute Postprandial Glucose Excursion at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.20" spread="2.68"/>
                    <measurement group_id="O2" value="0.02" spread="3.13"/>
                    <measurement group_id="O3" value="1.63" spread="2.47"/>
                    <measurement group_id="O4" value="3.14" spread="2.82"/>
                    <measurement group_id="O5" value="-0.14" spread="2.68"/>
                    <measurement group_id="O6" value="1.89" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial Glucose Excursion at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial Glucose Excursion at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.99" spread="3.26"/>
                    <measurement group_id="O2" value="-5.24" spread="3.82"/>
                    <measurement group_id="O3" value="-5.69" spread="3.06"/>
                    <measurement group_id="O4" value="-0.73" spread="3.40"/>
                    <measurement group_id="O5" value="-0.12" spread="3.22"/>
                    <measurement group_id="O6" value="0.79" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 60-minute Postprandial Glucose Excursion at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 60-minute Postprandial Glucose Excursion at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.29" spread="4.26"/>
                    <measurement group_id="O2" value="-16.51" spread="5.01"/>
                    <measurement group_id="O3" value="-19.44" spread="3.94"/>
                    <measurement group_id="O4" value="-3.95" spread="4.43"/>
                    <measurement group_id="O5" value="-13.83" spread="4.27"/>
                    <measurement group_id="O6" value="0.30" spread="3.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 15-minute Postprandial Insulin Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 15-minute Postprandial Insulin Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="57"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.58" spread="2.53"/>
                    <measurement group_id="O2" value="-1.04" spread="2.75"/>
                    <measurement group_id="O3" value="2.85" spread="2.32"/>
                    <measurement group_id="O4" value="1.18" spread="2.47"/>
                    <measurement group_id="O5" value="0.11" spread="2.52"/>
                    <measurement group_id="O6" value="-0.28" spread="2.24"/>
                    <measurement group_id="O7" value="2.19" spread="2.62"/>
                    <measurement group_id="O8" value="2.67" spread="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial Insulin Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial Insulin Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="57"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.95" spread="3.25"/>
                    <measurement group_id="O2" value="5.07" spread="3.61"/>
                    <measurement group_id="O3" value="2.40" spread="3.05"/>
                    <measurement group_id="O4" value="-0.89" spread="3.24"/>
                    <measurement group_id="O5" value="0.13" spread="3.23"/>
                    <measurement group_id="O6" value="3.23" spread="2.91"/>
                    <measurement group_id="O7" value="0.22" spread="3.05"/>
                    <measurement group_id="O8" value="9.87" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 60-minute Postprandial Insulin Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 60-minute Postprandial Insulin Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="57"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.03" spread="3.93"/>
                    <measurement group_id="O2" value="1.84" spread="4.29"/>
                    <measurement group_id="O3" value="0.75" spread="3.60"/>
                    <measurement group_id="O4" value="2.28" spread="3.83"/>
                    <measurement group_id="O5" value="-0.16" spread="3.93"/>
                    <measurement group_id="O6" value="1.82" spread="3.47"/>
                    <measurement group_id="O7" value="-3.61" spread="3.78"/>
                    <measurement group_id="O8" value="4.19" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 15-minute Postprandial Insulin Excursion at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 15-minute Postprandial Insulin Excursion at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="3.08"/>
                    <measurement group_id="O2" value="5.26" spread="3.76"/>
                    <measurement group_id="O3" value="1.98" spread="2.85"/>
                    <measurement group_id="O4" value="3.56" spread="3.14"/>
                    <measurement group_id="O5" value="-1.49" spread="3.05"/>
                    <measurement group_id="O6" value="4.42" spread="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial Insulin Excursion at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial Insulin Excursion at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="3.47"/>
                    <measurement group_id="O2" value="10.17" spread="4.25"/>
                    <measurement group_id="O3" value="1.43" spread="3.25"/>
                    <measurement group_id="O4" value="3.35" spread="3.53"/>
                    <measurement group_id="O5" value="5.36" spread="3.44"/>
                    <measurement group_id="O6" value="-0.70" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 60-minute Postprandial Insulin Excursion at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 60-minute Postprandial Insulin Excursion at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" spread="3.97"/>
                    <measurement group_id="O2" value="4.85" spread="4.82"/>
                    <measurement group_id="O3" value="-0.83" spread="3.63"/>
                    <measurement group_id="O4" value="2.02" spread="3.99"/>
                    <measurement group_id="O5" value="1.44" spread="4.01"/>
                    <measurement group_id="O6" value="-3.52" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 15-minute Postprandial C-peptide Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 15-minute Postprandial C-peptide Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="57"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.14"/>
                    <measurement group_id="O2" value="-0.08" spread="0.16"/>
                    <measurement group_id="O3" value="0.10" spread="0.13"/>
                    <measurement group_id="O4" value="0.08" spread="0.14"/>
                    <measurement group_id="O5" value="0.01" spread="0.14"/>
                    <measurement group_id="O6" value="0.01" spread="0.13"/>
                    <measurement group_id="O7" value="0.01" spread="0.15"/>
                    <measurement group_id="O8" value="0.17" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial C-peptide Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial C-peptide Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="57"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.18"/>
                    <measurement group_id="O2" value="0.11" spread="0.20"/>
                    <measurement group_id="O3" value="0.23" spread="0.17"/>
                    <measurement group_id="O4" value="-0.07" spread="0.18"/>
                    <measurement group_id="O5" value="0.12" spread="0.18"/>
                    <measurement group_id="O6" value="0.09" spread="0.16"/>
                    <measurement group_id="O7" value="-0.00" spread="0.20"/>
                    <measurement group_id="O8" value="0.31" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 60-minute Postprandial C-peptide Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 60-minute Postprandial C-peptide Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="57"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.20"/>
                    <measurement group_id="O2" value="0.35" spread="0.22"/>
                    <measurement group_id="O3" value="0.17" spread="0.19"/>
                    <measurement group_id="O4" value="0.12" spread="0.20"/>
                    <measurement group_id="O5" value="0.36" spread="0.20"/>
                    <measurement group_id="O6" value="0.17" spread="0.18"/>
                    <measurement group_id="O7" value="0.04" spread="0.21"/>
                    <measurement group_id="O8" value="0.20" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 15-minute Postprandial C-peptide Excursion at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 15-minute Postprandial C-peptide Excursion at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.16"/>
                    <measurement group_id="O2" value="0.42" spread="0.20"/>
                    <measurement group_id="O3" value="0.02" spread="0.15"/>
                    <measurement group_id="O4" value="0.02" spread="0.17"/>
                    <measurement group_id="O5" value="-0.04" spread="0.16"/>
                    <measurement group_id="O6" value="0.21" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial C-peptide Excursion at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial C-peptide Excursion at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.20"/>
                    <measurement group_id="O2" value="0.58" spread="0.24"/>
                    <measurement group_id="O3" value="0.16" spread="0.18"/>
                    <measurement group_id="O4" value="0.28" spread="0.20"/>
                    <measurement group_id="O5" value="0.32" spread="0.19"/>
                    <measurement group_id="O6" value="-0.08" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 60-minute Postprandial C-peptide Excursion at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 60-minute Postprandial C-peptide Excursion at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.22"/>
                    <measurement group_id="O2" value="0.59" spread="0.27"/>
                    <measurement group_id="O3" value="0.16" spread="0.20"/>
                    <measurement group_id="O4" value="0.27" spread="0.22"/>
                    <measurement group_id="O5" value="0.20" spread="0.22"/>
                    <measurement group_id="O6" value="0.13" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial Glucagon at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) glucagon 30 minutes after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial Glucagon at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) glucagon 30 minutes after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.84" spread="4.11"/>
                    <measurement group_id="O2" value="-10.92" spread="4.93"/>
                    <measurement group_id="O3" value="-11.26" spread="3.99"/>
                    <measurement group_id="O4" value="-5.81" spread="4.56"/>
                    <measurement group_id="O5" value="-9.04" spread="4.21"/>
                    <measurement group_id="O6" value="-1.98" spread="3.82"/>
                    <measurement group_id="O7" value="-14.97" spread="3.69"/>
                    <measurement group_id="O8" value="1.17" spread="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial Glucagon at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) glucagon 30 minutes after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial Glucagon at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) glucagon 30 minutes after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.39" spread="4.12"/>
                    <measurement group_id="O2" value="-6.06" spread="5.57"/>
                    <measurement group_id="O3" value="-12.64" spread="4.30"/>
                    <measurement group_id="O4" value="-17.21" spread="4.76"/>
                    <measurement group_id="O5" value="-11.90" spread="4.41"/>
                    <measurement group_id="O6" value="-3.64" spread="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial Free Fatty Acids (FFA) at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) FFA 30 minutes after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial Free Fatty Acids (FFA) at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) FFA 30 minutes after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mEg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="44"/>
                <count group_id="O7" value="39"/>
                <count group_id="O8" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.03"/>
                    <measurement group_id="O2" value="-0.03" spread="0.03"/>
                    <measurement group_id="O3" value="-0.07" spread="0.02"/>
                    <measurement group_id="O4" value="-0.08" spread="0.03"/>
                    <measurement group_id="O5" value="-0.05" spread="0.03"/>
                    <measurement group_id="O6" value="-0.02" spread="0.02"/>
                    <measurement group_id="O7" value="-0.17" spread="0.02"/>
                    <measurement group_id="O8" value="-0.16" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial FFA at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) FFA 30 minutes after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial FFA at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) FFA 30 minutes after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mEg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.03"/>
                    <measurement group_id="O2" value="-0.00" spread="0.03"/>
                    <measurement group_id="O3" value="-0.06" spread="0.03"/>
                    <measurement group_id="O4" value="-0.05" spread="0.03"/>
                    <measurement group_id="O5" value="-0.04" spread="0.03"/>
                    <measurement group_id="O6" value="-0.00" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial Glucagon Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) glucagon excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial Glucagon Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) glucagon excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.94" spread="3.64"/>
                    <measurement group_id="O2" value="-5.75" spread="4.42"/>
                    <measurement group_id="O3" value="-10.39" spread="3.60"/>
                    <measurement group_id="O4" value="-3.94" spread="4.02"/>
                    <measurement group_id="O5" value="-6.99" spread="3.76"/>
                    <measurement group_id="O6" value="3.58" spread="3.45"/>
                    <measurement group_id="O7" value="-8.54" spread="3.87"/>
                    <measurement group_id="O8" value="0.52" spread="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial Glucagon Excursion at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) glucagon excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial Glucagon Excursion at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) glucagon excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.96" spread="3.29"/>
                    <measurement group_id="O2" value="-4.46" spread="4.47"/>
                    <measurement group_id="O3" value="-6.80" spread="3.42"/>
                    <measurement group_id="O4" value="-10.36" spread="3.74"/>
                    <measurement group_id="O5" value="-8.56" spread="3.47"/>
                    <measurement group_id="O6" value="4.53" spread="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial FFA Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) FFA excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial FFA Excursion at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) FFA excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mEq/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="41"/>
                <count group_id="O7" value="39"/>
                <count group_id="O8" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.02"/>
                    <measurement group_id="O2" value="0.01" spread="0.02"/>
                    <measurement group_id="O3" value="-0.02" spread="0.02"/>
                    <measurement group_id="O4" value="0.00" spread="0.02"/>
                    <measurement group_id="O5" value="0.02" spread="0.02"/>
                    <measurement group_id="O6" value="-0.01" spread="0.02"/>
                    <measurement group_id="O7" value="-0.07" spread="0.02"/>
                    <measurement group_id="O8" value="-0.12" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Postprandial FFA Excursion at Week 12 in the 0-40 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial (after mealtime) FFA excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Postprandial FFA Excursion at Week 12 in the 0-40 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial (after mealtime) FFA excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mEq/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.02"/>
                    <measurement group_id="O2" value="-0.04" spread="0.03"/>
                    <measurement group_id="O3" value="0.02" spread="0.02"/>
                    <measurement group_id="O4" value="-0.01" spread="0.02"/>
                    <measurement group_id="O5" value="0.03" spread="0.02"/>
                    <measurement group_id="O6" value="-0.04" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 15-minute Insulinogenic Index at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Mean change from baseline in 15-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 15-minute Insulinogenic Index at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Mean change from baseline in 15-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="2.04"/>
                    <measurement group_id="O2" value="-0.31" spread="2.41"/>
                    <measurement group_id="O3" value="0.45" spread="1.88"/>
                    <measurement group_id="O4" value="-0.22" spread="1.22"/>
                    <measurement group_id="O5" value="0.04" spread="2.00"/>
                    <measurement group_id="O6" value="0.22" spread="1.80"/>
                    <measurement group_id="O7" value="-0.25" spread="4.52"/>
                    <measurement group_id="O8" value="-0.63" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 15-minute Insulinogenic Index at Week 12 in the 0-40 mg Cohort</title>
        <description>Mean change from baseline in 15-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 15-minute Insulinogenic Index at Week 12 in the 0-40 mg Cohort</title>
          <description>Mean change from baseline in 15-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="2.03"/>
                    <measurement group_id="O2" value="-0.19" spread="1.77"/>
                    <measurement group_id="O3" value="-0.13" spread="1.91"/>
                    <measurement group_id="O4" value="-0.34" spread="1.21"/>
                    <measurement group_id="O5" value="0.22" spread="1.54"/>
                    <measurement group_id="O6" value="-0.05" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Insulinogenic Index at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts.</title>
        <description>Mean change from baseline in 30-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Insulinogenic Index at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts.</title>
          <description>Mean change from baseline in 30-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="1.06"/>
                    <measurement group_id="O2" value="0.37" spread="0.76"/>
                    <measurement group_id="O3" value="0.31" spread="0.77"/>
                    <measurement group_id="O4" value="0.18" spread="0.81"/>
                    <measurement group_id="O5" value="0.71" spread="3.71"/>
                    <measurement group_id="O6" value="0.04" spread="0.72"/>
                    <measurement group_id="O7" value="0.46" spread="1.17"/>
                    <measurement group_id="O8" value="-0.05" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 30-minute Insulinogenic Index at Week 12 in the 0-40 mg Cohort</title>
        <description>Mean change from baseline in 30-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 30-minute Insulinogenic Index at Week 12 in the 0-40 mg Cohort</title>
          <description>Mean change from baseline in 30-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.99"/>
                    <measurement group_id="O2" value="0.84" spread="2.31"/>
                    <measurement group_id="O3" value="0.35" spread="0.97"/>
                    <measurement group_id="O4" value="-0.05" spread="0.50"/>
                    <measurement group_id="O5" value="0.25" spread="0.58"/>
                    <measurement group_id="O6" value="0.11" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Matsuda Index at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Mean change from baseline in Matsuda index achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts. The Matsuda index is a scale designed to give numbers between 0 and 12, with a linear relationship to other indices of insulin sensitivity. The higher the number, the better the insulin sensitivity (improvement).</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Matsuda Index at Week 6 in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Mean change from baseline in Matsuda index achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 &amp; 100 mg cohorts. The Matsuda index is a scale designed to give numbers between 0 and 12, with a linear relationship to other indices of insulin sensitivity. The higher the number, the better the insulin sensitivity (improvement).</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="57"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="1.36"/>
                    <measurement group_id="O2" value="0.31" spread="1.27"/>
                    <measurement group_id="O3" value="-0.04" spread="2.84"/>
                    <measurement group_id="O4" value="0.31" spread="1.76"/>
                    <measurement group_id="O5" value="-0.06" spread="2.49"/>
                    <measurement group_id="O6" value="-0.25" spread="1.91"/>
                    <measurement group_id="O7" value="0.86" spread="2.86"/>
                    <measurement group_id="O8" value="0.35" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Matsuda Index at Week 12 in the 0-40 mg Cohort</title>
        <description>Mean change from baseline in Matsuda index achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort. The Matsuda index is a scale designed to give numbers between 0 and 12, with a linear relationship to other indices of insulin sensitivity. The higher the number, the better the insulin sensitivity (improvement).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Matsuda Index at Week 12 in the 0-40 mg Cohort</title>
          <description>Mean change from baseline in Matsuda index achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort. The Matsuda index is a scale designed to give numbers between 0 and 12, with a linear relationship to other indices of insulin sensitivity. The higher the number, the better the insulin sensitivity (improvement).</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 12 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="2.81"/>
                    <measurement group_id="O2" value="0.34" spread="1.21"/>
                    <measurement group_id="O3" value="0.27" spread="3.90"/>
                    <measurement group_id="O4" value="0.78" spread="3.24"/>
                    <measurement group_id="O5" value="0.17" spread="3.68"/>
                    <measurement group_id="O6" value="-0.15" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in A1C at 2 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Mean change from baseline in A1C achieved at each dose of saxagliptin during the Follow-Up period at Week 14 in the 0-40 mg cohort and at Week 8 in the 0 &amp; 100 mg cohort.</description>
        <time_frame>Baseline, Week 14</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 14 (0-40 mg cohort) or Week 8 (0&amp;100 mg cohort), participants must have had a baseline and at least 1 follow-up period measurement. Week 14 and Week 8 assessments are the assessments closest to the respective target dates (or later assessments in the case of a tie).</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at 2 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Mean change from baseline in A1C achieved at each dose of saxagliptin during the Follow-Up period at Week 14 in the 0-40 mg cohort and at Week 8 in the 0 &amp; 100 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 14 (0-40 mg cohort) or Week 8 (0&amp;100 mg cohort), participants must have had a baseline and at least 1 follow-up period measurement. Week 14 and Week 8 assessments are the assessments closest to the respective target dates (or later assessments in the case of a tie).</population>
          <units>percentage of glycated hemoglobins</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="59"/>
                <count group_id="O7" value="41"/>
                <count group_id="O8" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.93"/>
                    <measurement group_id="O2" value="-0.84" spread="1.04"/>
                    <measurement group_id="O3" value="-0.78" spread="0.98"/>
                    <measurement group_id="O4" value="-0.66" spread="1.03"/>
                    <measurement group_id="O5" value="-0.69" spread="1.04"/>
                    <measurement group_id="O6" value="-0.25" spread="0.83"/>
                    <measurement group_id="O7" value="-1.15" spread="0.76"/>
                    <measurement group_id="O8" value="-0.45" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in A1C at 4 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Mean change from baseline in A1C achieved at each dose of saxagliptin during the Follow-Up period at Week 16 in the 0-40 mg cohort and at Week 10 in the 0 &amp; 100 mg cohort.</description>
        <time_frame>Baseline, Week 10, Week 16</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 16 (0-40 mg cohort) and Week 10 (0&amp;100 mg cohort), participants must have had a baseline and at least 1 follow-up period measurement. Week 16 and Week 10 assessments are the assessments closest to the respective target date (or later assessment in the case of a tie)</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at 4 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Mean change from baseline in A1C achieved at each dose of saxagliptin during the Follow-Up period at Week 16 in the 0-40 mg cohort and at Week 10 in the 0 &amp; 100 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 16 (0-40 mg cohort) and Week 10 (0&amp;100 mg cohort), participants must have had a baseline and at least 1 follow-up period measurement. Week 16 and Week 10 assessments are the assessments closest to the respective target date (or later assessment in the case of a tie)</population>
          <units>percentage of glycated hemoglobins</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="56"/>
                <count group_id="O7" value="41"/>
                <count group_id="O8" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.98"/>
                    <measurement group_id="O2" value="-0.72" spread="0.96"/>
                    <measurement group_id="O3" value="-0.64" spread="0.99"/>
                    <measurement group_id="O4" value="-0.57" spread="0.94"/>
                    <measurement group_id="O5" value="-0.53" spread="0.97"/>
                    <measurement group_id="O6" value="-0.24" spread="0.87"/>
                    <measurement group_id="O7" value="-1.01" spread="0.70"/>
                    <measurement group_id="O8" value="-0.43" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FSG at 2 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Mean change from baseline in FSG achieved at each dose of saxagliptin during Follow-Up period at Week 14 in the 0-40 mg cohort and at Week 8 in the 0 &amp; 100 mg cohort.</description>
        <time_frame>Baseline, Week 8, Week 14</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 14 (0-40 mg cohort) or Week 8 (0&amp;100 mg cohort), participants must have had a baseline and at least 1 follow-up period measurement. Week 14 and Week 8 assessments are the assessments closest to the respective target dates (or later assessments in the case of a tie).</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FSG at 2 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Mean change from baseline in FSG achieved at each dose of saxagliptin during Follow-Up period at Week 14 in the 0-40 mg cohort and at Week 8 in the 0 &amp; 100 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 14 (0-40 mg cohort) or Week 8 (0&amp;100 mg cohort), participants must have had a baseline and at least 1 follow-up period measurement. Week 14 and Week 8 assessments are the assessments closest to the respective target dates (or later assessments in the case of a tie).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="56"/>
                <count group_id="O7" value="43"/>
                <count group_id="O8" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.93" spread="36.86"/>
                    <measurement group_id="O2" value="-14.03" spread="34.62"/>
                    <measurement group_id="O3" value="-7.58" spread="29.35"/>
                    <measurement group_id="O4" value="-11.17" spread="33.97"/>
                    <measurement group_id="O5" value="-6.02" spread="38.40"/>
                    <measurement group_id="O6" value="-0.75" spread="29.11"/>
                    <measurement group_id="O7" value="-14.14" spread="26.14"/>
                    <measurement group_id="O8" value="-3.47" spread="26.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FSG at 4 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Mean change from baseline in FSG achieved at each dose of saxagliptin during the follow-up period at Week 16 in the 0-40 mg cohort and at Week 10 in the 0 &amp; 100 mg cohort.</description>
        <time_frame>Baseline, Week 10, Week 16</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 16 (0-40 mg cohort) and Week 10 (0&amp;100 mg cohort), participants must have had a baseline and at least 1 follow-up period measurement. Week 16 and Week 10 assessments are the assessments closest to the respective target date (or later assessment in the case of a tie)</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FSG at 4 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Mean change from baseline in FSG achieved at each dose of saxagliptin during the follow-up period at Week 16 in the 0-40 mg cohort and at Week 10 in the 0 &amp; 100 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 16 (0-40 mg cohort) and Week 10 (0&amp;100 mg cohort), participants must have had a baseline and at least 1 follow-up period measurement. Week 16 and Week 10 assessments are the assessments closest to the respective target date (or later assessment in the case of a tie)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="39"/>
                <count group_id="O8" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.82" spread="31.60"/>
                    <measurement group_id="O2" value="-11.55" spread="33.73"/>
                    <measurement group_id="O3" value="-6.65" spread="46.36"/>
                    <measurement group_id="O4" value="-9.05" spread="28.62"/>
                    <measurement group_id="O5" value="-0.91" spread="33.94"/>
                    <measurement group_id="O6" value="-2.04" spread="40.19"/>
                    <measurement group_id="O7" value="-7.82" spread="23.88"/>
                    <measurement group_id="O8" value="-5.97" spread="21.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fructosamine at 2 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Mean change from baseline in fructosamine achieved at each dose of saxagliptin during the Follow-up period at Week 14 in the 0-40 mg cohort and at Week 8 in the 0 &amp; 100 mg cohort.</description>
        <time_frame>Baseline, Week 8, Week 14</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 14 or Week 8, participants must have had a baseline and at least 1 post-baseline measurement. The Week 14 and Week 8 assessments are the assessments closest to the respective target dates (or later assessments in the case of a tie).</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fructosamine at 2 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Mean change from baseline in fructosamine achieved at each dose of saxagliptin during the Follow-up period at Week 14 in the 0-40 mg cohort and at Week 8 in the 0 &amp; 100 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 14 or Week 8, participants must have had a baseline and at least 1 post-baseline measurement. The Week 14 and Week 8 assessments are the assessments closest to the respective target dates (or later assessments in the case of a tie).</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="58"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.40" spread="35.18"/>
                    <measurement group_id="O2" value="-19.78" spread="33.80"/>
                    <measurement group_id="O3" value="-12.77" spread="37.92"/>
                    <measurement group_id="O4" value="-17.10" spread="39.36"/>
                    <measurement group_id="O5" value="-12.81" spread="32.41"/>
                    <measurement group_id="O6" value="-7.48" spread="34.15"/>
                    <measurement group_id="O7" value="-21.86" spread="31.39"/>
                    <measurement group_id="O8" value="-5.97" spread="23.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fructosamine at 4 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 &amp; 100 mg Cohorts</title>
        <description>Mean change from baseline in fructosamine achieved at each dose of saxagliptin during the Follow-up period at Week 16 in the 0-40 mg cohort and at Week 10 in the 0 &amp; 100 mg cohort.</description>
        <time_frame>Baseline, Week 10, Week 16</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 16 (0-40 mg cohort) and Week 10 (0&amp;100 mg cohort), participants must have had a baseline and at least 1 follow-up period measurement. Week 16 and Week 10 assessments are the assessments closest to the respective target date (or later assessment in the case of a tie)</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fructosamine at 4 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 &amp; 100 mg Cohorts</title>
          <description>Mean change from baseline in fructosamine achieved at each dose of saxagliptin during the Follow-up period at Week 16 in the 0-40 mg cohort and at Week 10 in the 0 &amp; 100 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 16 (0-40 mg cohort) and Week 10 (0&amp;100 mg cohort), participants must have had a baseline and at least 1 follow-up period measurement. Week 16 and Week 10 assessments are the assessments closest to the respective target date (or later assessment in the case of a tie)</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="56"/>
                <count group_id="O7" value="40"/>
                <count group_id="O8" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.60" spread="39.61"/>
                    <measurement group_id="O2" value="-8.02" spread="37.54"/>
                    <measurement group_id="O3" value="-11.02" spread="40.73"/>
                    <measurement group_id="O4" value="-19.44" spread="37.39"/>
                    <measurement group_id="O5" value="-10.14" spread="31.45"/>
                    <measurement group_id="O6" value="-7.05" spread="35.13"/>
                    <measurement group_id="O7" value="-15.25" spread="30.78"/>
                    <measurement group_id="O8" value="-10.00" spread="24.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in A1C at Week 6 by Baseline A1C Category in the 0 &amp; 100 Cohort</title>
        <description>Adjusted mean change from baseline in A1C achieved at each dose of saxagliptin at Week 6 in subjects with baseline A1C &lt;7%, ≥7% to &lt;8%, ≥8% to &lt;9%, and ≥9% in the 0 &amp; 100 mg cohort.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at Week 6 by Baseline A1C Category in the 0 &amp; 100 Cohort</title>
          <description>Adjusted mean change from baseline in A1C achieved at each dose of saxagliptin at Week 6 in subjects with baseline A1C &lt;7%, ≥7% to &lt;8%, ≥8% to &lt;9%, and ≥9% in the 0 &amp; 100 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;7% (n=8; n=12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.26"/>
                    <measurement group_id="O2" value="-0.18" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥7% to &lt;8% (n=20; n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.01" spread="0.41"/>
                    <measurement group_id="O2" value="-0.30" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥8% to &lt;9% (n=9; n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" spread="0.53"/>
                    <measurement group_id="O2" value="-0.34" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥9% (n=6; n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.10" spread="0.88"/>
                    <measurement group_id="O2" value="-0.83" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FSG at Week 6 in Subjects by Baseline FSG Category in the 0 &amp; 100 mg Cohort.</title>
        <description>Adjusted mean change from baseline in FSG achieved at each dose of saxagliptin at Week 6 in subjects with baseline FSG &lt;140 mg/dL, ≥140 mg/dL to &lt;180 mg/dL, and ≥ 180 mg/dL in the 0 &amp; 100 mg cohort.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FSG at Week 6 in Subjects by Baseline FSG Category in the 0 &amp; 100 mg Cohort.</title>
          <description>Adjusted mean change from baseline in FSG achieved at each dose of saxagliptin at Week 6 in subjects with baseline FSG &lt;140 mg/dL, ≥140 mg/dL to &lt;180 mg/dL, and ≥ 180 mg/dL in the 0 &amp; 100 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 140 mg/dL (n=17; n=17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.12" spread="12.51"/>
                    <measurement group_id="O2" value="1.29" spread="12.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>140 - &lt; 180 mg/dL (n=17; n=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.00" spread="19.47"/>
                    <measurement group_id="O2" value="0.07" spread="26.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥180 mg/dL (n=9; n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.89" spread="25.21"/>
                    <measurement group_id="O2" value="-19.50" spread="48.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 60 Minute Postprandial Glucose at Week 6 by Baseline Category in the 0 &amp; 100 mg Cohort</title>
        <description>Adjusted mean change from baseline in 60-minute postprandial glucose achieved at each dose of saxagliptin at Week 6 in subjects with baseline 60-minute postprandial glucose &lt;140 mg/dL, ≥140 to &lt;200 mg/dL, and ≥200 mg/dL in the 0 &amp; 100 mg cohort.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6, participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 60 Minute Postprandial Glucose at Week 6 by Baseline Category in the 0 &amp; 100 mg Cohort</title>
          <description>Adjusted mean change from baseline in 60-minute postprandial glucose achieved at each dose of saxagliptin at Week 6 in subjects with baseline 60-minute postprandial glucose &lt;140 mg/dL, ≥140 to &lt;200 mg/dL, and ≥200 mg/dL in the 0 &amp; 100 mg cohort.</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6, participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;140 mg/dL (n=1; n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.00" spread="0.00"/>
                    <measurement group_id="O2" value="11.33" spread="12.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥140 to &lt;200 mg/dL (n=17; n=12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.29" spread="21.44"/>
                    <measurement group_id="O2" value="-19.25" spread="25.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥200 mg/dL (n=20; n=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-62.10" spread="34.83"/>
                    <measurement group_id="O2" value="-21.35" spread="57.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving A1C &lt; 7% at Week 6 in the 0 &amp; 100 mg Cohort</title>
        <description>Percentage of participants achieving A1C &lt; 7%, the American Diabetic Association's defined goal for glycemia, at each dose of saxagliptin at Week 6 in the 0 &amp; 100 mg cohort.</description>
        <time_frame>Week 6</time_frame>
        <population>Randomized participants. To be included in the Week 6 LOCF analysis, subjects must have had at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving A1C &lt; 7% at Week 6 in the 0 &amp; 100 mg Cohort</title>
          <description>Percentage of participants achieving A1C &lt; 7%, the American Diabetic Association's defined goal for glycemia, at each dose of saxagliptin at Week 6 in the 0 &amp; 100 mg cohort.</description>
          <population>Randomized participants. To be included in the Week 6 LOCF analysis, subjects must have had at least 1 post-baseline measurement.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 60-minute Postprandial FFA Excursion at Week 6 in the 0 &amp; 100 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial FFA excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0 &amp; 100 mg cohort. (Note: this analysis was not performed.)</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 60-minute Postprandial FFA Excursion at Week 6 in the 0 &amp; 100 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial FFA excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0 &amp; 100 mg cohort. (Note: this analysis was not performed.)</description>
          <population>Randomized participants. To be included in analysis of change from baseline to Week 6 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 60-minute Postprandial Glucagon Excursion at Week 6 in the 0 &amp; 100 mg Cohort</title>
        <description>Adjusted mean change from baseline in postprandial glucagon excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0 &amp; 100 mg cohort. (Note: this analysis was not performed.)</description>
        <time_frame>Baseline, Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 60-minute Postprandial Glucagon Excursion at Week 6 in the 0 &amp; 100 mg Cohort</title>
          <description>Adjusted mean change from baseline in postprandial glucagon excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0 &amp; 100 mg cohort. (Note: this analysis was not performed.)</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Discontinuations During the Double-Blind Phase Due to Lack of Glycemic Control</title>
        <description>Number of participants discontinuing from the double-blind phase due to lack of glycemic control at Week 4 and Week 6. (Note: this analysis was not performed.)</description>
        <time_frame>Week 4, Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
          <group group_id="O7">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Discontinuations During the Double-Blind Phase Due to Lack of Glycemic Control</title>
          <description>Number of participants discontinuing from the double-blind phase due to lack of glycemic control at Week 4 and Week 6. (Note: this analysis was not performed.)</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Double-Blind Treatment Period in the 0-40 mg Cohort</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
        <time_frame>up to Week 12 for AEs; up to 30 days post-double-blind period but prior to follow-up period if any for SAEs and up to 30 days post-double-blind period for Discontinuations</time_frame>
        <population>All participants randomized and treated during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Double-Blind Treatment Period in the 0-40 mg Cohort</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
          <population>All participants randomized and treated during the double-blind period.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="76.6"/>
                    <measurement group_id="O3" value="77.8"/>
                    <measurement group_id="O4" value="87.0"/>
                    <measurement group_id="O5" value="75.0"/>
                    <measurement group_id="O6" value="79.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="1.9"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5"/>
                    <measurement group_id="O2" value="23.4"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="25.9"/>
                    <measurement group_id="O5" value="23.1"/>
                    <measurement group_id="O6" value="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.1"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="1.9"/>
                    <measurement group_id="O5" value="3.8"/>
                    <measurement group_id="O6" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Double-Blind Treatment Period in the 0 &amp; 100 mg Cohort</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
        <time_frame>up to Week 6 for AEs; up to 30 days post-double-blind period but prior to follow-up period if any for SAEs and up to 30 days post-double-blind period for Discontinuations</time_frame>
        <population>All participants randomized and treated during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Placebo (0 &amp; 100 Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Double-Blind Treatment Period in the 0 &amp; 100 mg Cohort</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
          <population>All participants randomized and treated during the double-blind period.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.9"/>
                    <measurement group_id="O2" value="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7"/>
                    <measurement group_id="O2" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Follow-up Period in the 0-40 mg Cohort</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
        <time_frame>From Week 12 to Week 16 for AEs; up to 30 days post follow-up in both cohorts for SAEs and Discontinuations</time_frame>
        <population>All participants treated during the follow-up period.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O5">
            <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          </group>
          <group group_id="O6">
            <title>Placebo (0-40 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Follow-up Period in the 0-40 mg Cohort</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
          <population>All participants treated during the follow-up period.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="37.9"/>
                    <measurement group_id="O4" value="37.5"/>
                    <measurement group_id="O5" value="42.6"/>
                    <measurement group_id="O6" value="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="7.1"/>
                    <measurement group_id="O3" value="3.4"/>
                    <measurement group_id="O4" value="12.5"/>
                    <measurement group_id="O5" value="4.3"/>
                    <measurement group_id="O6" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Follow-up Period in the 0 &amp; 100 mg Cohort</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
        <time_frame>From Week 6 to Week 10 for AEs; up to 30 days post follow-up in both cohorts for SAEs and Discontinuations</time_frame>
        <population>All participants treated during the follow-up period.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          </group>
          <group group_id="O2">
            <title>Placebo (0 &amp; 100 mg Cohort)</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Follow-up Period in the 0 &amp; 100 mg Cohort</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
          <population>All participants treated during the follow-up period.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Saxagliptin 10 mg (0-40 mg Cohort)</title>
          <description>The Saxagliptin 10 mg group includes data from subjects randomized to receive blinded Saxagliptin 10 mg for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Saxagliptin 100 mg (0 &amp; 100 mg Cohort)</title>
          <description>The Saxagliptin 100 mg group includes data from subjects randomized to receive blinded Saxagliptin 100 mg for 6 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Saxagliptin 2.5 mg (0-40 mg Cohort)</title>
          <description>The Saxagliptin 2.5 mg group includes data from subjects randomized to receive blinded Saxagliptin 2.5 mg for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>Saxagliptin 20 mg (0-40 mg Cohort)</title>
          <description>The Saxagliptin 20 mg group includes data from subjects randomized to receive blinded Saxagliptin 20 mg for 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Saxagliptin 40 mg (0-40 mg Cohort)</title>
          <description>The Saxagliptin 40 mg group includes data from subjects randomized to receive blinded Saxagliptin 40 mg for 12 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Saxagliptin 5 mg (0-40 mg Cohort)</title>
          <description>The Saxagliptin 5 mg group includes data from subjects randomized to receive blinded Saxagliptin 5 mg for 12 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Placebo (0 &amp; 100 mg Cohort)</title>
          <description>The placebo group includes data from subjects randomized to receive blinded placebo for 6 weeks.</description>
        </group>
        <group group_id="E8">
          <title>Placebo (0-40 mg Cohort)</title>
          <description>The placebo group includes data from subjects randomized to receive blinded placebo for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 7</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 7</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="38" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boaz Hirschberg</name_or_title>
      <organization>AstraZeneca Pharmaceuticals</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

